GGrantIndex
← Leaderboards

Winifred Masterson Burke Med Res Inst

White Plains, NY

Compare ↔
$149,464,996
Total funding
85
Grants

Funding over time

peak $15.8M · FY2005–25
$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$149,464,996 · 85

By mechanism

R01$117,624,588 · 47
P01$18,415,831 · 11
R21$4,175,805 · 9
DP2$2,795,126 · 1
RF1$2,075,563 · 1
R00$982,016 · 2

Investigators at Winifred Masterson Burke Med Res Inst

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Vibhu Vinodchandra Sahni$3,025,1553 gr2David J Simon$335,9941 gr3Shivakeshavan Ratnadurai Giridharan$304,9571 gr

Emerging Leaders

6–10 yrs in

1Edmund R Hollis$3,929,6664 gr2Pasquale Fonzetti$328,7851 gr

All-Time

Most funded here, all years

1Bruce S Kristal$16,485,39910 gr2Gary E Gibson$15,536,6277 gr3Sunghee Cho$13,269,4155 gr4Yutaka Yoshida$12,727,1485 gr5Neil Alan Shneider$8,442,0747 gr6Botir T. Sagdullaev$5,935,2273 gr7Harriet D. Baker$5,738,8702 gr8Jian Zhong$5,552,3682 gr

Largest grants

Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease$11,038,947
R01 · FY2023 · AG
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease$9,664,204
R01 · FY2022 · AG
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease$9,592,233
R01 · FY2025 · AG
Modulation of cortical networks, a new approach to spinal cord injury rehabilitation$2,775,000
DP2 · FY2017 · NS
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration$2,437,958
P01 · FY2016 · AG
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration$2,420,583
P01 · FY2018 · AG
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration$2,420,583
P01 · FY2020 · AG
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration$2,420,583
P01 · FY2017 · AG
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration$2,420,583
P01 · FY2019 · AG
The role of neuronal hyperexcitability and proteostasis in Alzheimer's disease$2,075,563
RF1 · FY2024 · AG
Mitochondrial Dysfunction in Neurodegeneration of Aging$1,636,811
P01 · FY2010 · AG
Mitochondrial Dysfunction in Neurodegeneration of Aging$1,626,788
P01 · FY2012 · AG
Mitochondrial Dysfunction in Neurodegeneration of Aging$1,626,785
P01 · FY2014 · AG
Mitochondrial Dysfunction in Neurodegeneration of Aging$1,626,781
P01 · FY2011 · AG
Mitochondrial Dysfunction in Neurodegeneration of Aging$1,537,309
P01 · FY2013 · AG
MITOCHONDRIAL DYSFUNCTION IN NEUROGEGENERATION OF AGING$1,430,806
P01 · FY2005 · AG
TRANSCRIPTIONAL RESPONSES TO MITOCHONDRIAL DYSFUNCTION$1,399,439
P01 · FY2009 · AG
MITOCHONDRIAL DYSFUNCTION IN NEUROGEGENERATION OF AGING$1,399,439
P01 · FY2009 · AG
MITOCHONDRIAL DYSFUNCTION IN NEUROGEGENERATION OF AGING$1,395,983
P01 · FY2006 · AG
TRANSCRIPTIONAL RESPONSES TO MITOCHONDRIAL DYSFUNCTION$1,360,888
P01 · FY2008 · AG